翻修全髋关节置换术中氨甲环酸最佳给药方案:多中心随机临床试验
该多中心随机试验将175例翻修全髋关节置换患者随机分配至4种氨甲环酸给药方案,发现各组术后血红蛋白下降、计算失血量和输血率均无显著差异,且等效性检验显示所有两两方案均等效。基于此,医生可根据实践和医院条件选择任一方案,但翻修全髋关节置换的输血率仍需进一步研究。
要点
- 四种氨甲环酸方案在翻修全髋关节置换中血液保护作用等效。
- 单剂静脉、双剂静脉、静脉联合局部、多剂口服方案失血量无差异。
- 尽管使用氨甲环酸,翻修全髋关节置换输血率仍为14%至18%。
核心结论
- 四种氨甲环酸给药方案在翻修全髋关节置换中具有等效的血液保护作用。
- 基于等效性,医生应选择最适合其实践和医院条件的方案。
研究设计与样本
- 多中心、随机临床试验,纳入175例翻修全髋关节置换患者,随机分至4种氨甲环酸方案组。
- 随机化基于翻修亚组以确保组间分布均衡,并进行意向性功效分析(α=0.05;β=0.80)确定每组需40例。
主要发现
- 术后血红蛋白下降:单剂静脉组3.4 g/dL,双剂静脉组3.6 g/dL,静脉联合局部组3.5 g/dL,多剂口服组3.4 g/dL(p=0.95)。
- 计算失血量组间无显著差异(p=0.90)。
- 输血率:单剂静脉组14%,双剂静脉组18%,联合组17%,多剂口服组17%(p=0.96)。
- 等效性检验显示所有两两方案均统计学等效(以血红蛋白下降>1 g/dL为临床相关差异)。
- 发生1例静脉血栓栓塞,组间无差异(p=1.00)。
关键数值与推荐
- 每组需40例以识别组间术后血红蛋白下降>1 g/dL的差异(α=0.05;β=0.80)。
- 等效性检验假设血红蛋白下降>1 g/dL为临床相关差异。
临床怎么用
- 翻修全髋关节置换中可选择四种氨甲环酸方案中的任一种,依据实践和医院条件决定。
- 尽管使用氨甲环酸,输血率仍较高,需进一步研究降低输血率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this multicenter, randomized trial was to determine the optimal dosing regimen of tranexamic acid (TXA) to minimize perioperative blood loss in revision total hip arthroplasty. METHODS: Six centers prospectively randomized 175 patients to 1 of 4 regimens: (1) 1-g intravenous (IV) TXA prior to incision (the single-dose IV group), (2) 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (the double-dose IV group), (3) a combination of 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (the combined IV and topical group), or (4) 3 doses totaling 1,950-mg oral TXA (the multidose oral group). Randomization was based on revision subgroups to ensure equivalent group distribution. An a priori power analysis (α = 0.05; β = 0.80) determined that 40 patients per group were required to identify a >1-g/dL difference in postoperative hemoglobin reduction between groups. Per-protocol analysis involved an analysis of variance, Fisher exact tests, and two 1-sided t tests for equivalence. Demographic and surgical variables were equivalent between groups. RESULTS: No significant differences were found between TXA regimens when evaluating reduction in hemoglobin (3.4 g/dL for the single-dose IV group, 3.6 g/dL for the double-dose IV group, 3.5 g/dL for the combined IV and topical group, and 3.4 g/dL for the multidose oral group; p = 0.95), calculated blood loss (p = 0.90), or transfusion rates (14% for the single-dose IV group, 18% for the double-dose IV group, 17% for the combined group, and 17% for the multidose oral group; p = 0.96). Equivalence testing revealed that all possible pairings were statistically equivalent, assuming a >1-g/dL difference in hemoglobin reduction as clinically relevant. There was 1 venous thromboembolism, with no differences found between groups (p = 1.00). CONCLUSIONS: All 4 TXA groups tested had equivalent blood-sparing properties in the setting of revision total hip arthroplasty, with a single venous thromboembolism reported in this high-risk population. Based on the equivalence between groups, surgeons should utilize whichever of the 4 investigated regimens is best suited for their practice and hospital setting. Given the transfusion rate in revision total hip arthroplasty despite TXA utilization, further work is required in this area. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
引用
- Sershon RA, Fillingham YA, Abdel MP, et al. The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty: A Multicenter Randomized Clinical Trial. J Bone Joint Surg Am. 2020. PMID: 33148955. doi:10.2106/JBJS.20.00010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。